The higher the bleeding risk, the greater the benefit of radial access in terms of mortality

Original title: Baseline bleeding risk and arterial access site practice in relation to procedural outcomes after percutaneous coronary intervention. Presenter: Mamas A. Mamas et al. J Am Coll Cardiol. 2014;64:1554-1564.

The transradial approach has been associated with reduced access site related bleeding complications as well as a reduced mortality in the context of PCI. It seems reasonable to assume that baseline bleeding risk could also influence the benefit associated to the transradial approach, but it has not yet been established.

This trial studied the relationship between baseline bleeding risk, the transradial approach and post PCI events of all patients included in the British Cardiovascular Intervention Society database.

Baseline bleeding risk was calculated with the modified Mehran score in 348689 patients undergoing PCI between the years2006 and 2011. Patients were divided according to score in 4 categories of risk (low <10, moderate 10-14, high 15-19 and very high ≥20). The impact of baseline risk was analyzed on mortality at 30 days, according to access site.

Radial access was associated to a reduction of 35% mortality at 30 days (OR 0.65, IC 95% 0.59 to 0.72; p < 0.0001) and this reduction was associated to baseline bleeding risk (for those with

Conclusion

The transradial approach was independently associated to a reduction of mortality at 30 days and the magnitude of this effect was associated to bleeding risk. PCI patients with higher risk of bleeding are the ones that most benefit from the transradial approach.

Editorial Comment

In this study of the daily practice it was observed that 43% of patients with the lowest bleeding risk received the radial approach and, unexpectedly, only 40% of patients with the highest bleeding risk saw the same benefit. Even though there is enough evidence to adopt the transradial approach in all patients, we should give special attention to those with higher risk of bleeding, risk that should be calculated prior to intervention and should be known by the operator for him to make an informed decision on the most appropriate access site.

SOLACI

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....